TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00129792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dietary supplement for weight loss
Description: The dietary supplement being investigated in this study is a natural product designed to reduce metabolic syndrome by decreasing hunger, increasing energy, and improving insulin function.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dietary supplement for weight loss
Description: The dietary supplement being investigated in this study is a natural product designed to reduce metabolic syndrome by decreasing hunger, increasing energy, and improving insulin function.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and counseling for weight loss
Description: Hour and a half weight loss education session weekly for 12 weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Education and counseling for weight loss
Description: Hour and a half weight loss education session weekly for 12 weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education and counseling for weight loss
Description: Hour and a half weight loss education session weekly for 12 weeks.
Study: NCT01250483

Intervention type: OTHER
Intervention: PSA measurement, uroflowmetry, IPSS, transrectal ultrasonography
Study: NCT03793686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBCLN-003
Description: Investigational drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03060967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based tasks
Description: Computer-based tasks designed to assess size and time discrimination capacities of food and control images

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based tasks
Description: Computer-based tasks designed to assess size and time discrimination capacities of food and control images
Study: NCT02965066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test Catheter
Description: Newly developed intermittent catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test Catheter
Description: Newly developed intermittent catheter
Study: NCT05818618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol Topical Gel
Description: Topic Clobetasol gel applied locally on OLP lesions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral gel applied locally on OLP lesions.
Study: NCT02043613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contextually enhanced physical surroundings of exercise
Description: Different physical surroundings of exercise may affects the patients differently and consequently influence the effect of exercise. The exercise rooms are different from each other on parameters such as source of lighting, acoustics, materials and decorations.~The differences with the physical surroundings of exercise is the primary intervention for this study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise
Description: The neuromuscular exercise program is the same across the two exercise groups. Consequently, this intervention is not the primary intervention of this study. The exercise program is based on the previously reported NEMEX program designed for patients with hip or knee osteoarthritis, originally published by Ageberg et al, 2010 in BMCMusculoskeletal Disorders.
Study: NCT02965066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Speedicath
Description: Marketed Coloplast Speedicath catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Speedicath
Description: Marketed Coloplast Speedicath catheter
Study: NCT03288740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Description: A dose of 0.25 mg semaglutide gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide 0.5 mg)
Description: A dose of 0.25 mg semaglutide placebo gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Description: A dose of 0.25 mg semaglutide gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide 1.0 mg)
Description: A dose of 0.25 mg semaglutide placebo gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
Study: NCT01861145

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bed Alarm
Description: The bed alarm is a device that is worn at night with a sensor in the child's underwear. The alarm will activate when the child urinates, helping the brain to link the sensation of a full bladder with wakening.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bed Alarm
Description: The bed alarm is a device that is worn at night with a sensor in the child's underwear. The alarm will activate when the child urinates, helping the brain to link the sensation of a full bladder with wakening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasonex
Description: Intranasal steroids are used by otolaryngologists as first line treatment for adenotonsillar hypertrophy in children with suspected sleep-disordered breathing and obstructive sleep apnea. The spray helps to shrink the size of the adenoids and tonsils, diminishing the amount of tissue obstructing the child's airway.
Study: NCT04376099

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcutaneous oxygen pressure measurement during the treadmill test
Description: Calculation of the decrease from rest of oxygen pressure (DROP) throughout the period of rest exercise and recovery.~The DROP is calculated as chanegs on each limb probe minus changes on a chest reference probe from rest.~Analysis of the recovery period of the recordings will be done to seach for recovery 50% and 90% from the minimal DROP observed Evaluation of calf and non calf pain during the tests. Evaluation of calf and non calf (buttock or thigh) ischemia during the tests. Ischemia being defined as a monimal DROP lower than minus 15 mmHg.
Study: NCT02383498

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Standard of care

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: Standard of care
Study: NCT02664207

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Fetal Repair of Myelomeningocele
Description: Fetal repair of myelomeningocele in women with additional medical factors that would have excluded them from this treatment under the MOMs trial inclusion/exclusion criteria
Study: NCT02565732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum toxin type A, Dose A, Topical

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum toxin type A, Dose B, Topical

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo, Dose C, Topical
Study: NCT05461183

Intervention type: OTHER
Intervention: Retrospective database analysis
Description: This study will review data provided by the BCPDR from April 1, 2008 to March 31, 2021.
Study: NCT02383498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wGT3X-BT Actigraph
Description: wGT3X-BT is small, non-invasive, portable watch accelerometer worn on the subject's wrist for Cycle 1 through Cycle 9

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: wGT3X-BT Actigraph
Description: wGT3X-BT is small, non-invasive, portable watch accelerometer worn on the subject's wrist for Cycle 1 through Cycle 9
Study: NCT02043613

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular exercise
Description: The neuromuscular exercise program is the same across the two exercise groups. Consequently, this intervention is not the primary intervention of this study. The exercise program is based on the previously reported NEMEX program designed for patients with hip or knee osteoarthritis, originally published by Ageberg et al, 2010 in BMCMusculoskeletal Disorders.
Study: NCT00118131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study: NCT00283491

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Lactobacillus plantarum 299v
Description: 10\^11 cfu/meal in 2 meals on 2 consecutive days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Lactobacillus plantarum 299v
Description: Inactive form of the active treatment but with the fermentation products in the same concentration
Study: NCT02680431

Intervention type: OTHER
Intervention: Blood sample
Description: 10 mL venous blood sample for analysis of plasma

Intervention type: OTHER
Intervention: Blood sample
Description: 10 mL venous blood sample for analysis of plasma
Study: NCT01908413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUDC-427
Description: CUDC-427 as an oral formulation administered daily on a 14 days on/7 days off schedule
Study: NCT06305130

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00476632

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: 50 Minute Interview
Study: NCT02245061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: paired pulses cortical electrical stimulation
Study: NCT00687310

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational intervention
Description: Tailored asthma education based on needs assessment
Study: NCT01362127

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiochemotherapy
Description: Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
Study: NCT01962181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritalin
Description: Patients with ADHD and healthy subjects will be examined under Ritalin or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04461366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monopolar radiofrequency
Description: The RF electrode was moved randomly for 30 seconds over each scar. The total duration of the treatment session is only 5 minutes for each cheek. It takes 15 minutes if the forehead and 2 cheeks are affected.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed dye laser
Description: PDL was applied for the affected areas with no pre-treatment regimens or topical anaesthetics. There was no requirement for skin cooling.
Study: NCT01007565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periarticular anesthetics injection
Description: Members in the PI group received intra-operative periarticular injections and additional sensory nerve blocks just before skin closure . For the periarticular injections and additional sensory block, local analgesic solution was injected into the wrist joint, joint capsule, periosteum, subcutaneous tissue, skin, and around the anterior and posterior interosseous nerves and the superficial radial nerve. A volume of 2ml was injected into the joint capsule and periosteum, and of 3ml into the wrist joint, subcutaneous tissue, skin and into each nerve.
Study: NCT01822574

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cutting Guide Technique
Description: The guide is clamped onto the patella and tightened so that it remains stable. The guide has a slot that allows insertion of a standard sagittal saw blade, and this slot guides the blade as it is advanced across the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Haptic Feedback Technique
Description: It consists of a free hand cut (no guide used) with a standard sagittal saw that is oriented based on osteo-cartilaginous landmarks and haptic palpation of the patella by the surgeon. The resection thickness/obliquity can be altered based on haptic feedback (use of the sense of touch) of the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four Quadrant Technique
Description: Resection is performed in a free handed fashion, but after resection, the thickness of the patella is measured separately in all four quadrants (superolateral, superomedial, inferomedial, and inferolateral). Additional resection is performed as needed based on the quadrant measurements and the measurements are repeated after each resection until satisfactory resection thickness and symmetry are obtained.
Study: NCT02582866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: * Pharmaceutical Form: Oral tablets~* Concentration: 50 mg~* Route of Administration: Oral administration
Study: NCT06429319

Intervention type: DEVICE
Group type: OTHER
Intervention: hydrous biopolymer with silver ions Argiform
Description: Patients will receive an injection of MD NOLTREX™ into the target knee joint. MD will be administered in accordance with the instructions for use of MD NOLTREX™: 4.0 ml per injection (2.5 + 1.5 ml, or 2.0 + 2.0 ml from two syringes through one needle \[one puncture\]) at intervals of one week. The course within this open study is a maximum of 2 injections. The number of injections is determined by the doctor depending on the stage of gonarthrosis and the clinical response
Study: NCT02963441

Intervention type: DEVICE
Intervention: LumineticsCore (formerly IDX-DR)
Description: Prospective analysis on an existing subgroup of subjects in the US pivotal study, version 01 and version 02.
Study: NCT00814918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-ALA with Blu-U Light
Description: 20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to DUSA Blu-U light (417nm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-ALA with Candela V-beam Pulse Dye Laser
Description: 20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to Candela V-beam Pulsed Dye Laser (595 nm).
Study: NCT03055663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedation by watching virtual reality sedative program
Description: Patients watch three-dimensional virtual reality program with headset and headphone during surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedation by using intravenous sedative
Description: Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
Study: NCT02071849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HAART 200 Aortic Valve Annuloplasty Device
Description: Surgical repair of bicuspid aortic valve using the HAART 200 Aortic Valve Annuloplasty Device .
Study: NCT04144114

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProHydrolase®
Description: Subjects received 250mg of ProHydrolase® with 25g whey protein mixed together in a drink
Study: NCT03331224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OTSC
Description: OTSC placement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Standard therapy (combining two methods)
Description: endoscopic standard therapy (two methods, e.g. clip and injection)
Study: NCT03714347

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cerebral oxygen monitoring
Description: probes will be placed on eyebrows on forehead

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: routine monitoring
Description: We will use routine monitoring intervention such as hate rate, arterial pressure, BIS. cerebral oxygen monitoring will not be applied to this group
Study: NCT03750071

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXM01
Description: Ty21a transformed with a eukaryotic VEGFR-2 Expression Plasmid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Monoclonal anti-PD-L1 Antibody
Study: NCT00405652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated Mycophenolate sodium (EC-MPS)
Description: experimental
Study: NCT02001363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide (Novo Nordisk, Bagsværd, Denmark)
Description: once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: liraglutide placebo (Novo Nordisk)
Description: once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days
Study: NCT04144114

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: Subjects received 25g of whey protein powder mixed to together in a drink

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00499200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRA-444
Study: NCT02394158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT05278026

Intervention type: OTHER
Intervention: guideline recommended routine treatment

Intervention type: OTHER
Intervention: guideline recommended routine treatment

Intervention type: OTHER
Intervention: guideline recommended routine treatment
Study: NCT02487966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS): active (Soterix ©)
Description: Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. For active tDCS, the subject will undergo stimulation for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS): active (Soterix ©)
Description: Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. For active tDCS, the subject will undergo stimulation for 20 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Therapy: active
Description: Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Therapy: active
Description: Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS): sham (Soterix ©)
Description: Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. The subject will undergo stimulation for 20 minutes. This is the same parameters as the active one, except the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS): sham (Soterix ©)
Description: Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. The subject will undergo stimulation for 20 minutes. This is the same parameters as the active one, except the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
Study: NCT00293150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eplerenone
Study: NCT00821145

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Description: AAA patients operated using a conventional incision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic AAA resection
Description: laparoscopic AAA resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic stapler anastomosis
Description: laparoscopic AAA resection, proximal anastomosis performed with a stapler
Study: NCT01019252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.